BRD9 and rhabdoid tumor: Protein-engineering and inhibitor studies targeting BRD9 have shown promise in overcoming epigenetically-defined drug resistance [14], and single or combinatorial effects of BRD9 inhibitors with doxorubicin or carboplatin also resulted in anti-proliferative effects in five malignant rhabdoid tumor cell lines [15].